The US Food and Drug Administration (FDA) on Thursday finalized two guidances providing recommendations to drugmakers on evaluating potential drug-drug interactions (DDIs) for new drugs through ...
The US Food and Drug Administration (FDA) has released a new draft guidance describing what should and should not be included in the Drug Interactions (DIs) section for human prescription drug and ...
FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information FDA ...
FDA moves shaping drug development and oversight include new gene therapy guidance, clinical trial transparency efforts, and recent drug approvals.
Since the FDA began publishing its rejections of drug approval filings in July last year, companies have become more ...
The FDA in a complete response letter to Replimune maintained its original objection to the single-arm trial the biotech used ...
The FDA has issued an advisory to consumers, urging them not to buy or use an array of products that, on labeling, contain ...
ORION CORPORATION PRESS RELEASE 20 APRIL 2026 at 16.00 EEST Orion Pharma’s ODM-212 Granted Orphan Drug Designation in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results